Long COVID Syndrom: Charakterisierung Eines Neuen Krankheitsbildes
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- self-addressed Quality of life
研究概览
简要总结
Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.
详细描述
Some people are very hesitant to recover from a COVID-19 infection and present persistent symptoms. The participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. Therefore, a special interdisciplinary consultation was built. The consulatation is not only addressed to people who have been hospitalized due to COVID-19, but also to those with mild symptoms during infection. During the consultation hours, personal health data are collected that serves as the basis for this research project.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Long COVID syndrome
- •age >= 18 years
- •Informed consent
排除标准
- 未提供
结局指标
主要结局
self-addressed Quality of life
时间窗: once through study completion, an average of 6 months
Short form health 36 questionnaire with 8 domains, each rated from 0-100. The higher the score the better subjective quality of life.
Medical history
时间窗: once through study completion, an average of 6 months
List of relevant morbidities assessed as present/not present by medical interview (e.g. respiratory, cardial, neurological, psychiatric diseases by interview and medical records)
Thoracic pain
时间窗: once through study completion, an average of 6 months
assessed by medical interview (reported as yes or no)
Fibrosis
时间窗: once through study completion, an average of 6 months
Assessed by chest CT, rated as present/not present
Myocardial damage
时间窗: once through study completion, an average of 6 months
Assessed by myocardial damage, rated as present/not present
Dyspnea
时间窗: once through study completion, an average of 6 months.
modified medical research council (scale from 0 to 4). The higher the score the worse the symptoms.
次要结局
未报告次要终点
研究者
Christian Clarenbach
Sponsor Investigator
University of Zurich